Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904‐Z

Hunt, Richard H.; Armstrong, David; Yaghoobi, Mohammad; James, Cindy; Chen, Y.; Leonard, Jennifer; Shin, Jai Moo; Lee, E.; Tang-Liu, Diane; Sachs, George

doi:10.1111/j.1365-2036.2008.03725.x

Cited by 40 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its pharmacokinetic effects prior to food intake (either breakfast, lunch, dinner or a nighttime snack; normal dietary habits) were bioequivalent, with a similar plasma t½ (1.27-1.44 h) and no significant differences in mean 24-h intragastric pH (37)(38)(39)(40).…”

Section: How Can the Action Of Ppis Be Modified?mentioning

confidence: 89%

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Sobrino-Cossío

López-Alvarenga

Remes-Troche

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

The Montreal Definition and Classification divides Gastroesophageal Reflux Disease (GERD) into esophageal symptomatic syndromes (and with mucosal damage) and extraesophageal syndromes (with acid established association and proposed association). In typical GERD symptoms, an 8-week treatment with PPIs is satisfactory in most cases (> 90%). Response rates to PPIs in GERD are highly variable, as they also rely on an appropriate clinical diagnosis of the disease; endoscopy differentiates the macroscopic GERD phenotype. The non-erosive variety (50-70% prevalence) has a different symptomatic response rate, as gastric acid is not the sole etiology of symptoms. The possible explanations of treatment failure include treatment adherence, PPI metabolism alterations and characteristics, and inadequate diagnosis. Refractory symptoms are related to gastric content neutralization by the chronic use of PPIs.Extraesophageal manifestations are associated with other pathophysiological mechanisms where an autonomic nervous system disturbance gives rise to symptoms. In these clinical entities, the relationship between symptoms and acid needs to be established in order to determine the use of PPIs, or consider other drugs. In other words, so as to "custom-tailor the best-fitting therapy" we need to answer the questions for whom, for what, how and for how long. Finally, PPI safety and tolerability are factors to be considered in elderly patients requiring chronic PPI use, who usually have chronic concomitant illnesses.

show abstract

Section: How Can the Action Of Ppis Be Modified?mentioning

confidence: 89%

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Sobrino-Cossío

López-Alvarenga

Remes-Troche

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

“…Alevium once daily showed a 1.9-fold increase in serum half-life as compared with esomeprazole. After 5 days of treatment, Alevium demonstrated a significantly higher mean 24-h intragastric pH, nocturnal median pH, and percentage of time intragastric pH was greater than 4 as compared with esomeprazole ( P = 0.0001) [34] (Table 6.2).…”

Section: Agn 201904-z (Alevium)mentioning

confidence: 96%

Novel Upcoming Therapies

Maradey–Romero

Fass

2015

Diagnosis and Treatment of Gastroesophageal Reflux Disease

View full text Add to dashboard Cite

“…For example, 20 % of GERD patients continue to have reflux symptoms despite maximal PPI therapy, due to the presence of poorly suppressed nocturnal acid secretion. A novel sulfonamide prodrug of omeprazole AGN904, with delayed absorption is capable of maintaining intragastric pH [ 5.0 for 24 h/day, promises to be effective for the recalcitrant 20 % of GERD patients with prominent nocturnal secretion [43], and also for the eradication of Hp which become persistent and Fig. 16 The outcomes of infection by Helicobacter pylori.…”

Section: Current Situation Of Clinical Use Of Ppismentioning

confidence: 99%

Gastric Acid-Dependent Diseases: A Twentieth-Century Revolution

Sachs

Shin²,

Munson

et al. 2014

Dig Dis Sci

View full text Add to dashboard Cite

Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904‐Z

Abstract: SUMMARYBackground AGN 201904-Z is a new, slowly absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) rapidly converted to omeprazole in the systemic circulation giving a prolonged residence time.

Cited by 40 publications

References 22 publications

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Novel Upcoming Therapies

Gastric Acid-Dependent Diseases: A Twentieth-Century Revolution

Contact Info

Product

Resources

About